AI
DNLI icon

Alphabet Inc’s Denali Therapeutics DNLI Stock Holding History

Alphabet Inc’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-536,411
Closed -$8.18M – 18
2018
Q2 		$8.18M Sell
536,411
-30,255
-5% -$570K 0.69% 14
2018
Q1 		$11.2M Hold
566,666
– – 1.81% 9
2017
Q4 		$8.86M Buy
+566,666
New +$10.2M 2.4% 6

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Alphabet Inc's DNLI Position: Q3 2018 in Review

Alphabet Inc sold out of Denali Therapeutics (DNLI) in Q3 2018, closing a stake of 536,411 shares — an estimated $8.18M sold.

Alphabet Inc first reported a position in DNLI in Q4 2017 and held it in 3 quarters. The position peaked at $11.2M in Q1 2018. 78 funds tracked by Wall St. Rank hold DNLI as of Q3 2018.

  • Alphabet Inc reported no remaining Denali Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Alphabet Inc sold 536,411 Denali Therapeutics shares in Q3 2018, an estimated $8.18M.
  • Alphabet Inc first reported a position in Denali Therapeutics in Q4 2017 and held it in 3 quarters.
  • Alphabet Inc's Denali Therapeutics position peaked at $11.2M in Q1 2018.
  • 78 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2018.

Based on Alphabet Inc's 13F filing for Q3 2018, filed 15 Nov 2022.